GSK 2282512A

Drug Profile

GSK 2282512A

Alternative Names: FLU Q-QIV; FluLaval Quadrivalent; Flulaval Tetra; FLuZactal Tetra; GSK-2282512A; GSK-2833489A; Quadrivalent seasonal influenza vaccine - GlaxoSmithKline

Latest Information Update: 23 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline Biologicals
  • Class Antivirals; Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 21 Nov 2016 Registered for Influenza virus infections (Prevention, In infants, In children) in USA (IM)
  • 02 Feb 2016 Registered for Influenza virus infections (Prevention, In infants, In children, In adolescents, In adults) in Mexico (IM) before February 2016
  • 02 Feb 2016 GlaxoSmithKline files sBLA for inclusion of infants and children aged 6 months to 35 months for Influenza virus infections (Prevention) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top